An innovative technology
to treat serious illnesses
Buccal administration to deliver pharmaceutical active ingredients to all cells:
Interfering RNAs, metal ions, peptides …
With AONYS delivery platform, Medesis Pharma paves the way for new treatments !
News
New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients
March, 2023
Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases
November, 2022
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy
April 5, 2022
AONYS®, a unique platform for drug administration
AONYS® is a micro-emulsion for buccal administration, invisible to immune system and protected transport in HDL lipoproteins, allowing intracellular release with passage across the blood–brain barrier.
Our Goals
Medesis Pharma is a clinical-stage Pharmaceutical Biotechnology company developing innovative technology (AONYS®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment.
Neurodegenerative diseases
Virology
